Orphan Drugs for CNS Diseases: R&D and Market 2014-2024

CNS(中枢神経系)疾病の向けオーファンドラッグ:R&Dおよび市場(2014-2024)

◆タイトル:Orphan Drugs for CNS Diseases: R&D and Market 2014-2024
◆商品コード:Visiongain-4052612
◆調査・発行会社:visiongain
◆発行日:2014年1月
◆ページ数:130
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single user licence(1名使用)GBP1,799 ⇒換算¥278,845見積依頼/購入/質問フォーム
Dept Licence(部署内共有可)GBP2,999 ⇒換算¥464,845見積依頼/購入/質問フォーム
Site Licence(同一国内社内共有可)GBP4,999 ⇒換算¥774,845見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"CNS(中枢神経系)疾病の向けオーファンドラッグ:R&Dおよび市場(2014-2024)"について調査・分析し、エグゼクティブサマリー、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、研究開発パイプライン分析、専門家の見解、結論などの情報をお届けいたします。

Uncommon nerve disorders – new study explains technological and commercial prospects
What’s the future of medicines for rare central nervous system (CNS) disorders? Visiongain’s new report gives you predictions for those therapies. Stay ahead. There you explore sales results, technologies, R&D trends, opportunities, and revenue forecasts.
So see what’s possible for treating unusual neurological conditions. Avoid missing out. You gain data and financial analysis for that industry and market, appraising its outlooks. Find technological progress and commercial prospects, seeing potential gains.
Read on to explore those treatments and find what their future could be worth.
Forecasts and other analyses for therapy of rare (orphan) neurodegenerative disorders
Our new study reveals sales predictions to 2024 at overall world, submarket, product, and national level. For those therapies, you investigate where the money lies. Find potentials.
Besides forecasting revenues to 2024, that work shows historical results, growth rates, and market shares. There you get feel for technologies, regulatory outlooks, and developments (R&D). You also gain 41 tables, 40 charts, and two interviews with the industry.
Knowledge to help your work and save time, helping your influence
Our report strives to help your business research, analyses, and decisions on treatments for debilitating CNS diseases. There also see how you can save time. And find how you could benefit your authority through better understanding the present and future.
So the following sections explain what you get in that new investigation.
Forecasting of that world market and its main segments – you explore possibilities
What’re the secrets of that industry’s progress? What’s its potential? Discover in our work overall world revenue to 2024 for orphan-drug CNS therapy.
Also in that report you see individual revenue predictions to 2024 for four therapeutic submarkets at world level:
• Huntington’s disease (HD)
• Amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease, motor neurone disease)
• Myasthenia gravis (MG)
• Other treatment applications.
How will those categories expand? Which classes of therapy can generate most money? So you assess outlooks for sales growth, seeing where you can gain.
There you explore competition and rising sales for treating the rarer abnormalities causing neurodegeneration, autoimmune neuromuscular disorder, and other nerve disease.
You also assess top products’ futures.
Predictions of leading agents’ revenues
Find sales outlooks for brands, too, seeing how they compete and succeed. Our study shows you individual revenue forecasts to 2024 for four marketed drugs:
• Xenazine (tetrabenazine)
• Rilutek (riluzole)
• Mestinon (pyridostigmine)
• Imuran (azathioprine).
There you find products and years with highest predicted sales and growth. Also you examine competitors. You see what’s happening, then, understanding challenges, competition, opportunities, and potentials.
Our study also divides its overall prediction into geographical regions.
Healthcare in leading national markets – what outlooks for those CNS drug sales?
In developed and developing countries, opportunities for providers of orphan neurological medicines will increase from 2014 to 2024. See where and how, finding sales potentials.
Our analyses show you individual revenue forecasts to 2024 for 11 national markets:
• United States (US)
• Japan
• EU leaders – Germany, France, the UK, Italy, and Spain (EU5)
• BRIC nations – Brazil, Russia, India, and China.
There you find countries with highest revenues, demand, and potential sales growth. Our work explains. You assess needs and demands for those specialist medicines.
Explore, too, how that neurological pharma technology benefits developers, producers, marketers, and sellers. Our work shows you, discussing issues.
Events and forces for developing, producing, marketing, and selling CNS orphan medicines
Our report shows you issues and events affecting that pharmaceuticals sector from 2014, including these:
• Candidates in development – R&D pipelines – for those indications
• Benefits of orphan drug designation
• Treatment needs – unmet and under-met – stimulating demand
• Regulatory incentives for developers, producers, and sellers.
And these influences:
• Drug launches expected and their implications for that industry and market
• Potential for orphan CNS products in emerging national markets
• Innovations – including drug-device combinations, neurotrophic factors to reverse disease, cellular therapy, and stimulating of neuronal growth
• Companion diagnostics and personalised medicine.
There you explore political, economic, social, and technological questions, investigating outlooks for commerce. Discover what the future holds.
Examine, then, what stimulates and restrains players in that industry, and affects results.
Companies and 2018 market value – find prospects for success
What happens next? From 2014 new and novel treatments and regulations there encourage investments, medical advances, and higher revenues.
Our report, then, predicts the world market for drugs treating those rare CNS conditions will exceed $2.5bn in 2018. There big pharma and specialty companies can gain. Explore how.
There you examine activities of many companies, including these:
• GlaxoSmithKline (GSK)
• Lundbeck
• Valeant Pharmaceuticals
• Teva Pharmaceutical Industries
• BrainStorm Cell Therapeutics.
R&D in that industry holds strengths, and from 2014 there will arise many opportunities. From this decade, patients, payers, and pharmaceutical companies will benefit.
And you discover how that market can perform, staying ahead in knowledge.
Ways Orphan Drugs for CNS Diseases: R&D and Market 2014-2024 helps you
In particular, our investigation gives you these advantages:
• Revenues there to 2024 at world level, for 4 submarkets, and 4 top products – examine outlooks for production, marketing, and sales
• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia – assess developed and developing countries for potential revenues
• Prospects for established competitors, emerging companies, and new entrants – explore portfolios, results, strategies, and developmental activities.
Information found nowhere else, helping your searches, analyses, and plans
That study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. Explore the commercial possibilities.
With that data you’re less likely to fall behind in knowledge or miss opportunity. Being free to choose, you find how you could save time and effort with our study, helping your decisions.
Predictions for that medical biotechnology – gain now by trying our report
Our new report is for everyone investigating applied neurology and medicines for CNS disorders. So find projections you need. Avoid missing out, then – please order now.

【レポートの目次】

1. Executive Summary
1.1 Orphan Drugs for CNS Diseases: Market Overview
1.2 Report Contents – Chapter Overviews
1.3 Research and Analysis Methods
2. Introduction to Orphan Drugs for CNS Disorders
2.1 Defining Orphan Diseases
2.2 What are the Major Orphan CNS Indications?
2.2.1 Huntington’s Disease
2.2.2 Amyotrophic Lateral Sclerosis (ALS)
2.2.3 Myasthenia Gravis
2.2.4 Other Orphan CNS Indications
2.3 Orphan Drug Designation: Providing Incentives to Companies
2.3.1 What Benefits Come with Orphan Drug Designation?
2.4 Demand for Orphan Drugs Gathers Momentum
2.4.1 Development of Orphan Drugs
3. The World Orphan CNS Drugs Market, 2014-2024
3.1 How Large Was the Orphan Drugs Market in 2013?
3.1.1 Huntington’s Disease: The Largest Orphan CNS Disease Sector in 2012
3.2 The Orphan CNS Drug Market: Revenue Forecast, 2013-2024
3.2.1 What Will Drive Growth in the Market to 2024?
3.2.2 What Will Restrain the Market From 2014-2024?
3.3 Orphan Drugs in Huntington’s Disease
3.3.1 Huntington’s Disease: Submarket Forecast, 2013-2024
3.3.1.1 Huge Unmet Need to Drive HD Treatment Market
3.3.1.2 Enactment of New Law in US May Add Growth Impetus
3.4 Orphan Drugs in Amyotrophic Lateral Sclerosis
3.4.1 Amyotrophic Lateral Sclerosis: Submarket Forecast, 2013-2024
3.4.1.1 New Drug Launches Will Provide Market Recovery Following Patent Expiry of Rilutek
3.5 Orphan Drugs in Myasthenic Gravis
3.5.1 Myasthenia Gravis: Submarket Forecast, 2013-2024
3.5.1.1 Clinical R&D into New Treatments Keep Patients Hopeful
4. Leading National Markets for Rare CNS Indications 2014-2024
4.1 Regional Breakdown of The Orphan CNS Drug Market
4.2 Leading National Markets: Revenue Forecasts, 2013-2024
4.3 The US: The Leading Market for Orphan CNS Drugs in 2012
4.3.1 Orphan Drug Regulations in the US
4.3.2 Benefits for Orphan Drug Developers
4.3.3 The US Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.4 Orphan Drugs in Leading EU Markets
4.4.1 The EU5 Orphan CNS Drug Market: Revenue Forecasting, 2013-2024
4.4.1.1 The Incentives for Orphan Drug Development in the EU
4.4.2 Orphan CNS Drugs in the EU5: Submarket Revenue Forecasts, 2013-2024
4.4.2.1 The German Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.4.2.2 The French Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.4.2.3 The UK Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.4.2.4 The Spanish Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.4.2.5 The Italian Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.5 The Japanese Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.5.1 Orphan Drug Regulations and Benefits in Japan
4.6 Potential for Orphan CNS Drugs in Emerging National Markets, 2013-2024
4.6.1 The Chinese Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.6.2 The Indian Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.6.2.1 Large Patient Population to Draw Drug Developers to India
4.6.3 The Russian Orphan CNS Drug Market: Revenue Forecast, 2013-2024
4.6.3.1 Attempts to Introduce Orphan Designation and Incentives 2010-2013
4.6.4 The Brazilian Orphan CNS Drug Market: Revenue Forecast, 2013-2024
5. Outlooks for Leading Orphan CNS Drugs 2014-2024
5.1 Huntington’s Disease Treatments
5.1.1 Xenazine (Tetrabenazine; Lundbeck/Valeant Pharmaceuticals)
5.1.1.1 Omerus Pipeline HD Treatment Receives Orphan Designation
5.1.1.2 Xenazine: Revenue Forecast, 2013-2024
5.2 Amyotrophic Lateral Sclerosis Treatments
5.2.1 Rilutek (Riluzole; Covis Pharmaceuticals)
5.2.1.1 Patent Expiry to Cause Influx of Generic Treatments
5.2.1.2 Rilutek: Revenue Forecast, 2013-2024
5.3 Myasthenia Gravis Treatments
5.3.1 Mestinon (Pyridostigmine bromide; Valeant Pharmaceuticals)
5.3.1.1 Lack of Novel Treatments to Compete With Branded Drug
5.3.1.2 Mestinon: Revenue Forecast, 2013-2024
5.3.2 Imuran (Azathioprine; Prometheus Laboratories/Aspen Pharmacare)
5.3.2.1 Serious Adverse Events May Further Reduce Use of Imuran
5.3.2.2 Imuran: Revenue Forecast, 2013-2024
6. Orphan CNS Drugs: R&D Pipelines
6.1 Drugs in the Huntington’s Disease Pipeline
6.1.1 ALN-HTT (Alnylam Pharmaceuticals/Medtronic Inc.): Drug-Device Combination Therapy
6.1.2 HD-02 (Avicena Group Inc.): Correcting the Body’s Cellular Energy
6.1.3 CERE-120 (Ceregene Inc.): Delivering Neurotrophic Factors to Reverse Disease Process
6.1.4 Lead Compounds (Chaperone Therapeutics): Targeting Protein Misfolding
6.1.5 CX929 (Cortex Pharmaceuticals): Ampakine Treatment to Encourage Neuronal Growth
6.1.6 EPI-743 (Edison Pharmaceuticals): Redox Therapy in Preclinical Testing
6.1.7 GSK356278 (GSK): Respiration Treatment in Line for Additional HD Indication
6.1.8 Modified Antisense Oligo-Nucleotides (Isis Pharmaceuticals): Partnering with Roche to Aid Drug Discovery
6.1.9 NsG33 (Meteorin; NsGene A/S): Neurotrophic Protein Shown to Stimulate Neurite Growth in Preclinical Studies
6.1.10 LSD-1/MAO-B Inhibitor (Oryzon Genomics): Reducing Enzyme Activity May Provide Therapeutic Benefit
6.1.11 PBT2 (Prana Biotechnology): Targeting Metal-Protein Interactions to Reduce Protein Aggregation
6.1.12 PRO289 (Prosensa): Lowering Levels of Mutant Gene Proteins
6.1.13 RP103 (Raptor Pharmaceutical Corporation): Cysteamine Treatment Receives Orphan Designation
6.1.14 Zinc DNA Transcription Factors (Sangamo Biosciences/Shire AG): Switching Genes On and Off
6.1.15 Selisistat (SEN196; Siena Biotechnology): Orphan Drug Targeting Sirtuin Protein Inhibition in Phase II Development
6.1.16 Huntexil (Teva Pharmaceuticals): Neutralizing Dopaminergic Activity
6.2 Drugs in the Amyotrophic Lateral Sclerosis Pipeline, 2013
6.2.1 ALS-02, ALS-05 and ALS-08 (The Avicena Group): Designated Orphan Drug in Advanced Clinical Testing
6.2.2 NurOwn™ (BrainStorm Cell Therapeutics): Stem Cell Treatment to Replace Damaged Cells
6.2.3 Tirasemtiv (CK-2017357; Cytokinetics): Skeletal Muscle Activator Advances to Phase II Trials
6.2.4 E0302 (Mecobalamin; Eisai): Vitamin B12 Therapy Shown to Improve Muscle Wasting
6.2.5 Ozanezumab (GSK1223249; GSK): Monoclonal Antibody Treatment Recruiting Patients for Phase II Trial
6.2.6 Radicut (Edaravone; Mitsubishi Tanabe): Free Radical Scavenger in Advanced Trials
6.2.7 Region Specific Stem Cells (Neuralstem): Neuronal Stem Cell Therapy in Preclinical Testing
6.2.8 NP001 (Neuraltus Pharmaceuticals): Altering Macrophage Activity
6.2.9 sNN0029 (NeuroNova): Growth Factor Treatment Shown to Improve Muscle Strength
6.2.10 TDI-132 (Gilenya™; Novartis & The ALS Therapy Development Institute): Therapy to Counteract Aggressive Immune Cells
6.3 Drugs in the Myasthenia Gravis Pipeline, 2013
6.3.1 Soliris® (Eculizumab; Alexion Pharmaceuticals): Blood Disorder Treatment Investigated as Potential MG Therapy
6.3.2 BHT-3034 (Bayhill Therapeutics): Vaccine Therapy to Reverse Harmful Immune Responses
6.3.3 BKT130 (Biokine Therapeutics): Chemokine Inhibitor
6.3.4 CK-2017357 (Tirasemtiv; Cytokinetics): Designated Orphan Drug Tested in Multiple Indications
7. Orphan Drugs in CNS: Industry Trends, 2014-2024
7.1 Orphan Drugs in CNS: Strengths and Weaknesses, 2013-2024
7.2 Orphan Drugs in CNS: Opportunities and Threats, 2013-2024
7.3 Orphan Drugs in CNS: STEP Analysis, 2013-2024
7.3.1 Social Factors
7.3.1.1 Ethical Considerations in Funding Orphan Drug Development
7.3.2 Technological Developments
7.3.2.1 Increased Understanding of Disease Will Drive Innovation
7.3.3 Economic Pressures
7.3.3.1 Discounts in Drug Prices Will Increase Accessibility
7.3.4 Political Issues
7.3.4.1 Harmonising Global Regulatory Pathways
7.4 Trends in Orphan CNS Drug Development
7.4.1 Clinical Trials for Orphan Drugs
7.4.1.1 Are Adverse Events More Acceptable for Orphan Drugs?
7.4.1.2 Challenges and Opportunities in Patient Recruitment
7.4.2 Biomarkers for Orphan CNS Indications
7.4.2.1 Companion Diagnostics: Driving Personalised Medicine
7.4.3 The Role of Public Funding in Orphan Drug Development
7.5 Commercialising Orphan Drugs in CNS
7.5.1 Pricing of Orphan Drugs May Become Crucial to Success
7.5.2 Market and Patient Access Are Crucial for Orphan Drug Success
7.5.3 Repositioning Drugs for Orphan CNS Indications
7.5.3.1 Expanding Beyond Orphan Indications
7.5.4 Big Pharma and Orphan Drugs
7.5.4.1 Orphan Drugs Fit the Personalised Medicine Model
7.5.5 Common Market Entry Strategies
7.5.6 Orphan Indications as an Opportunity for Generic Drug Manufacturers
8. Research Interviews
8.1 Dr Tsao-Nivaggioli, CEO and Board Member, Avicena Group
8.1.1 Avicena Group
8.1.2 Rare Diseases and Applying for Orphan Drug Status
8.1.3 HD-02: Targeting the Body’s Cellular Energy Systems
8.1.4 Challenges in Developing Orphan Drugs
8.1.5 Future Growth Opportunities and Perspective for the Market
8.2 Respondent from Edison Pharmaceuticals
8.2.1 Edison Pharmaceuticals
8.2.2 Defining Orphan Disease and Drug Submissions in Target Markets
8.2.3 The Market Potential (and Risk) of Pursuing Treatments for Mitochondrial Diseases
8.2.4 Company Alliances and Future Prospects for the Market
9. Conclusions from Our Study
9.1 The State of the Orphan CNS Drugs Market
9.2 Renewed Interest in Rare CNS Diseases will Stimulate that Market
9.3 The US will Maintain its Market Dominance from 2014-2024
9.4 High Price of Treatments May Limit Market Potential



List of Tables
Table 1.1 Currency Exchange Rates
Table 1.2 Common Abbreviations Used in this Report
Table 2.1 EU Prevalence Statistics for Selected Rare CNS Indications, 2013
Table 3.1 Global Orphan CNS Drug Market: Revenue ($m) and Market Share (%) by Sector, 2012
Table 3.2 Global Orphan CNS Drug Market: Overall Market and Revenue Forecasts by Sector ($m, AGR %, CAGR %), 2013-2024
Table 3.3 Global Orphan CNS Drug Market: Submarket Shares (%), 2012-2024
Table 3.4 Huntington's Disease Submarket: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.5 Amyotrophic Lateral Sclerosis Submarket: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.6 Myasthenia Gravis Submarket: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.1 Global Orphan CNS Drug Market: Revenue ($m) and Market Share (%) by Region, 2012
Table 4.2 Global Orphan CNS Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) by Region, 2013-2024
Table 4.3 Global Orphan CNS Drug Market: Regional Submarket Shares (%),2012-2024
Table 4.4 US Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.5 EU5 Orphan CNS Drug Market: Revenue ($m) and Market Share (%) by Country, 2012
Table 4.6 EU5 Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %) by Country, 2013-2024
Table 4.7 Fee Reductions (%) Available for SMEs Developing Orphan Drugs in the EU, 2013
Table 4.8 German Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.9 French Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.10 UK Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.11 Spanish Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.12 Italian Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.13 Japanese Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.14 Chinese Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.15 Indian Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.16 Russian Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.17 Brazilian Orphan CNS Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 5.1 Top Orphan CNS Drugs: Revenues ($m) and Leading Revenue Shares (%), 2012
Table 5.2 Xenazine: Revenue ($m), 2009-2012
Table 5.3 Xenazine: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 5.4 Rilutek: Revenue ($m), 2010-2012
Table 5.5 Rilutek: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 5.6 Mestinon: Revenue ($m), 2010-2012
Table 5.7 Mestinon: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 5.8 Imuran: Revenue ($m), 2008-2012
Table 5.9 Imuran: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 6.1 Selected Pipeline Candidates in Development for Huntington's Disease, 2012
Table 6.2 Selected Pipeline Candidates in Development for ALS, 2013
Table 6.3 Selected Pipeline Candidates in Development for Myasthenia Gravis, 2013
Table 7.1 Global Orphan CNS Drug Market: Strengths and Weaknesses, 2013-2024
Table 7.2 Global Orphan CNS Drug Market: Opportunities and Threats, 2013-2024
Table 9.1 Global Orphan CNS Drug Market: Revenue ($m, CAGR %), and Market Share (%) by Sector, 2012, 2018 & 2024
Table 9.2 Global Orphan CNS Drug Market: Revenue ($m, CAGR %) and Market Share (%) by Region, 2012, 2018 & 2024
List of Figures
Figure 2.1 Orphan Disease Prevalence by Country/Region, 2013
Figure 2.2 Orphan Drugs Clinical Pipeline by Therapeutic Category, 2012
Figure 2.3 Orphan Drug Designation Benefits in Major Markets, 2013
Figure 3.1 Orphan Drug Approvals in the US, 2000-2013
Figure 3.2 Global Orphan CNS Drug Market: Share (%) by Sector, 2012
Figure 3.3 Global Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 3.4 Global Orphan CNS Drug Market: Submarket Shares (%), 2018
Figure 3.5 Global Orphan CNS Drug Market: Submarket Shares (%), 2024
Figure 3.6 Global Orphan CNS Drug Market: Drivers and Restraints, 2014-2024
Figure 3.7 Huntington's Disease Market: Revenue Forecast ($m), 2013-2024
Figure 3.8 Amyotrophic Lateral Sclerosis Market: Revenue Forecast ($m), 2013-2024
Figure 3.9 Myasthenia Gravis Market: Revenue Forecast ($m), 2013-2024
Figure 4.1 Global Orphan CNS Drug Market: Share (%) by Region, 2012
Figure 4.2 Global Orphan CNS Drug Market: Share (%) by Region, 2018
Figure 4.3 Global Orphan CNS Drug Market: Share (%) by Region, 2024
Figure 4.4 US Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.5 EU5 Orphan CNS Drug Market: Share (%) by Country, 2012
Figure 4.6 EU5 Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.7 German Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.8 French Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.9 UK Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.10 Spanish Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.11 Italian Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.12 Japanese Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.13 Chinese Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.14 Indian Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.15 Russian Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.16 Brazilian Orphan CNS Drug Market: Revenue Forecast ($m), 2013-2024
Figure 5.1 Top Orphan CNS Drug: Revenue Shares (%), 2012
Figure 5.2 Xenazine: Revenue ($m), 2009-2012
Figure 5.3 Xenazine: Revenue Share (%) by Region, 2012
Figure 5.4 Xenazine: Revenue Forecast ($m), 2013-2024
Figure 5.5 Rilutek: Revenue ($m), 2010-2012
Figure 5.6 Rilutek: Revenue Forecast ($m), 2013-2024
Figure 5.7 Mestinon: Revenue ($m), 2010-2012
Figure 5.8 Mestinon: Revenue Forecast ($m), 2013-2024
Figure 5.9 Imuran: Revenue ($m), 2008-2012
Figure 5.10 Imuran: Revenue Forecast ($m), 2013-2024
Figure 9.1 Global Orphan CNS Drug Market: Revenue ($m) by Sector, 2012, 2018 & 2024
Figure 9.2 Global Orphan CNS Drug Market: Revenue ($m) by Region, 2012, 2018 & 2024


【掲載企業】

Alexion Pharmaceuticals
Agência Nacional de Vigilância Sanitária (ANVISA, Brazil)
Alnylam Pharmaceuticals
Apotex
Aspen Pharmacare
Avicena Group
Bayhill Therapeutics
BHR Pharma
Biogen Idec
Biokine Therapeutics
Biovail
BrainStorm Cell Therapeutics
California's Stem Cell Agency
Cambridge Laboratories
Ceregene
Chaperone Therapeutics
Committee for Orphan Medicinal Products (COMP)
Core Pharmaceuticals
Cortex Pharmaceuticals
Covis Pharmaceuticals
Cytokinetics
Edison Pharmaceuticals
Eisai
European Commission
European Medicines Agency (EMA)
European Union
Food and Drug Administration (FDA, US)
Glenmark Generics
Global Pharmaceuticals (generics division of Impax Laboratories
GlaxoSmithKline (GSK)
Huntington's Disease Society of America (HDSA)
Isis Pharmaceuticals
Lundbeck
Massachusetts General Hospital
Medtronic
Ministry of Health, Labor and Welfare (MHLW, Japan)
Mitsubishi Tanabe
National Institute for Health and Care Excellence (NICE)
National Institute for Neurological Disorders and Stroke (NINDS)
Neuralstem
Neuraltus Pharmaceuticals
NeuroNova
NeuroSearch
Novartis
NsGene
Omerus Corporation
Oryzon Genomics
Pfizer
Prana Biotechnology
Prestwick Pharmaceuticals
Prometheus Laboratories
Prosensa
Raptor Pharmaceuticals
Rare Disease UK
Roche
Roxane Pharmaceuticals
Russian Ministry of Health and Social Development (MOHSD)
Sangamo Biosciences
Sanofi
Shire
Siena Biotechnology
State Food and Drug Administration (SFDA, China)
Sun Pharmaceutical Industries
Teva Pharmaceuticals
The ALS Therapy Development Institute
University Hospital Tübingen
University of Kyoto
Valeant Pharmaceuticals
World Health Organisation (WHO)
Zydus Pharmaceuticals


★調査レポート[CNS(中枢神経系)疾病の向けオーファンドラッグ:R&Dおよび市場(2014-2024)] ( Orphan Drugs for CNS Diseases: R&D and Market 2014-2024 / Visiongain-4052612) 販売に関する免責事項
[CNS(中枢神経系)疾病の向けオーファンドラッグ:R&Dおよび市場(2014-2024)] ( Orphan Drugs for CNS Diseases: R&D and Market 2014-2024 / Visiongain-4052612) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆